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Oxidative stress (OS) is a common pathogenic factor involved in the onset of several diseases in humans, from immunologic
disorders to malignancy, being a serious public health problem. In perinatal period, OS has been associated with adverse
outcome of pregnancy and neonatal diseases. Dangerous eﬀects of OS are mediated by increased production of free radicals
(FRs) following various mechanisms, such as hypoxia, ischemia reperfusion, hyperoxia, inﬂammation, mitochondrial
dysfunction, Fenton chemistry, and prostaglandin metabolism. FRs have short half-life, and their measurement in vivo is faced
with many challenges. However, oxyradical derivatives are stable and thus may be measured and monitored repeatedly. The
quantiﬁcation of OS is based on the measurement of speciﬁc biomarkers in biologic ﬂuids and tissues, which reﬂect induced
oxidative damage to lipids, proteins, and DNA. Prostanoids, non–protein-bound iron (NPBI), and advanced oxidation protein
products (AOPP) are actually considered truly speciﬁc and reliable for neonatal injury. Deﬁning reference values for these
biomarkers is necessary to investigate their role in neonatal diseases or also to evaluate the success of treatments. In this work,
we wanted to deﬁne laboratory reference values for biomarkers of OS in a healthy population of term newborns.
1. Introduction
Oxidative stress (OS) has been deﬁned “a state where
oxidative forces exceed the antioxidant systems due to loss
of the balance between them” [1]. OS reﬂects the tissue
damage resulting from an imbalance between excessive gen-
eration of oxidant compounds and insuﬃcient antioxidant
defense mechanisms [2]. Oxidant compounds are extremely
reactive species capable of independent existence that con-
tains one or more unpaired electron, named free radicals
(FRs). They are either endogenous and/or exogenous [1, 3].
Because of their high reactivity, they can abstract electrons
from other compounds to obtain stability. Thus, the attacked
molecule loses its electron and becomes a FR itself, begin-
ning a chain-reaction cascade, which ﬁnally damages the
organism’s structure and functions. OS is well known to
be involved in the pathogenesis of lifestyle-related diseases,
including hypertension, diabetes mellitus, ischemic diseases,
malignancies, or Alzheimer’s disease, Parkinson’s disease,
and amyotrophic lateral sclerosis [1, 3, 4]. Oxidative com-
pounds are also physiologically relevant in inﬂammation
and tissue repair processes. Hence, they represent some
defense mechanisms against microorganisms and malig-
nant cells as well as tissue healing and remodeling [4].
OS is known to be harmful because of the FR that
attacks biological molecules, like lipids or proteins, and
also DNA. Still, OS has also a useful role in physiologic
adaptation and in the regulation of intracellular signal
transduction [5]. Oxidative damage has been identiﬁed in
the pathogenesis of many preterm newborn diseases, such
as retinopathy of prematurity (ROP), bronchopulmonary
dysplasia (BPD), necrotizing enterocolitis (NEC), patent duc-
tus arteriosus (PDA), periventricular leukomalacia (PVL), and
intraventricular hemorrhage (IVH) [6–11]. Hypoxia, hyper-
oxia, ischemia, and inﬂammation are main mechanisms of
FR overproduction [12–19]. After the occurrence of
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hypoxia-ischemia, iron ions, serving as transitionmetal mole-
cules catalyzing hydroxyl radical production via the Fenton
reaction and the Haber-Weiss cycle, accumulate in cells.
Iron and FRs may result in DNA strand breaks [20], pro-
tein and lipid peroxidation [21], and cellular inﬂammation
and death [22, 23].
The accurate measurement of OS in vivo is necessary to
investigate their role in lifestyle diseases or also to evaluate
the success of treatment. FRs have very short half-life (of
the order of few seconds), and their measurement in vivo is
faced with many challenges. However, oxyradical derivatives
(e.g., hydrogen peroxide or lipid hydroperoxides) are stable
and have long half-life (hours to weeks) and thus may be
measured and monitored repeatedly.
The quantiﬁcation of OS is based on the measurement
of speciﬁc biomarkers in biologic ﬂuids and tissues, which
reﬂect induced oxidative damage to lipids, proteins, and
DNA or an increased risk for injury to macromolecules.
Several biomarkers have been proposed for OS detection,
but only a small number of them can be considered truly
speciﬁc and reliable for OS injury; these include prostanoids,
non–protein-bound iron (NPBI), and advanced oxidation
protein products (AOPP) [11, 24, 25].
1.1. Prostanoids. Prostanoids are a family of lipid mediators
generated by the action of cyclooxygenase on long-chain
unsaturated fatty acids. The mechanism involved in their
formation implies that FR insult causes hydrogen abstraction
from arachidonic acid and addition of molecular oxygen to
form a peroxyl radical [26]. The following intermediates
undergo double 5-exo-trig cyclization and addition of second
molecular oxygen to form prostaglandin G2-like compounds,
which are rapidly reduced to F2-IsoPs [27, 28]. These pros-
tanoids are more stable compared with other peroxidation
products, such as aldehydes or peroxyl radicals; thus, they
can be detected in biologic ﬂuids [29]. Prostanoids can be
measured in plasma, tissues, cells, urine, cerebral spinal
ﬂuid, bile, and bronchoalveolar lavage ﬂuid [30] for the
assessment of in situ oxidative injury. F2-IsoP detection
and measurement requires sophisticated and expensive
methods, such as liquid chromatography/mass spectrome-
try. IsoPs are chemically stable in vitro and in vivo and are
speciﬁc and reliable markers of lipid peroxidation. They
are thus reliable markers of in situ oxidative injury [30].
1.2. Non–Protein-Bound Iron (NPBI). In physiologic condi-
tions, iron is safely sequestered by transport proteins, such
as transferrin and lactoferrin, and stored in proteins, such
as ferritin and hemosiderin [31].
Because iron ions cannot be free in plasma, the term
NPBI was introduced to indicate a low-molecular-mass iron
form, free from binding to plasma proteins. NPBI levels can
be measured using high-performance liquid chromatography
[32]. Iron toxicity is inversely proportional to the presence of
ferritin, which is able to bind and detoxify ferrous ion, and
directly proportional to the quantity of hydrogen peroxide
to produce hydroxyl radicals through the Fenton reaction.
Furthermore, lipid exposure to high concentration of NPBI
leads to the formation of IsoPs.
Non–protein-bound iron is a marker of potential OS
because it indicates increased susceptibility to oxidative
damage especially in in vivo studies [24].
1.3. Advanced Oxidation Protein Products (AOPP).AOPP is a
very important biomarker of OS because the proteins are the
major targets of FRs, being present and abundant in cells,
plasma, and most tissues [11]. It was severally reported that
AOPP level increases in hypoxic newborns, especially pre-
term babies [25, 33]. Radical-induced damage to proteins is
not the terminal process of a reaction but is an enhancer
of tissue damages, very common in preterm babies. AOPP
remain stable during sample storage both at −20 and at
−80°C for six months, allowing for batched analysis of
progressive specimens [11]. AOPP are measured using
spectrophotometry on a microplate reader. The instruments
were calibrated with chloramine-T solutions that absorb at
340 nm in the presence of potassium iodide.
RIs of the OS biomarkers in cord blood are important for
screening, diagnosis, and monitoring of perinatal diseases.
Reference values for these biomarkers are currently lacking.
The aim of this study is to produce the reference intervals
(RIs) for OS markers in cord blood.
2. Materials and Methods
The study was conducted in 120 term newborns (58 males
and 62 females), with a gestational age (GA) between 38
and 42 weeks, born from vaginal delivery in Siena, Policlinico
le Scotte, AOU Senese, Italy, from 01/01/2016 to 30/04/2016.
None of the infants required medical care. Newborns with
clinical signs of hypoxia ischemia, infection, major congeni-
tal malformations, inborn errors of metabolism, and blood
group incompatibility were excluded from the study. Birth
weight was adequate for gestational age in all enrolled
newborns. 120 samples of cord blood for F2-IsoPs, AOPP,
and NPBI were examined. The treatment of the sample was
previously standardized according to internal protocols of
the laboratory. The cordo blood was collected in serum tubes
(Sarstedt, S-Monovette Serum gel) and centrifuged promptly
after collection, and serum aliquots were preserved at −80°C
in Sarstedt Eppendorf Type D (CLSI/NCCLS document
H18) [34].
In some aliquots (for the assay of F2-IsoPs), BHT
(butylated hydroxytoluene) was added to inhibit the lipidic
peroxidation in vitro. All samples were collected within
four months.
Inclusion criteria were applied in the second days of
life evaluating the clinical conditions and the history of
the neonate.
The number of enrolled cases was decided following
IFCC guidelines. The Clinical Laboratory Standards Institute
(CLSI) recommends a minimum of 120 individuals; this
is the minimum sample size required to determine 90%
conﬁdence intervals (CI) for the 95th percentile reference
limits (2.5th and 97.5th percentiles).
The preanalytical phase has been standardized: the
permanence time in the freezer is not higher than four
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months; for these reasons, we have chosen to enlist a smaller
number of cases, but certainly more homogeneous.
The LC-MS/MS method of Casetta et al. [30] was
followed for determination of F2-IsoPs (API 4000 Tandem
Mass Spectrometer coupled with HPLC Agilent 1200
series), the method of Paﬀetti et al. [24] for NPBI with
HPLC-DAD system (Agilent 1100 series), and the spectro-
photometric method of Witko-Sarsat et al. [35] for AOPP
detection.
The methods that we used describe the analytical
imprecision, the limit of detection, the linearity, the recovery,
the interference characteristic, and the traceability of the
results. Hemolytic samples were excluded. All samples for
each method were measured in double, in three diﬀerent days
in the same conditions, with the same lot and technologist
variability, from the same people. Previously, tests on the
storage stability were made.
3. Statistical Analysis
We used an “a posteriori” approach.
The indirect method of sampling suggested by Horn and
Pesce [36] was used to estimate IRs for F2-IsoP, NPBI, and
AOPP in cord blood sample of newborn.
The descriptive statistical analysis, after the D’Agostino-
Pearson test for normality of population was performed,
included median and IQR. The RIs were calculated using a
nonparametric method as described in the CLSI guidelines
C28-A3. The IFCC recommends that a minimum number
of subjects of 120 should be recruited to derive RIs.
Statistics were performed using SPSS version 20 (IBM
Corporation, NY, USA).
4. Results
Serum samples from 120 umbilical cords were used to
calculate reference RIs for 3 speciﬁc markers of OS measured
with chromatography (HPLC), liquid chromatography/mass
spectrometry (LC/MS/MS), or spectrophotometry methods.
All infants were from a normal pregnancy ended in
a spontaneous delivery. During pregnancy, the mothers
followed the same living and eating style.
Demographic and clinical characteristics of the study
population are reported in Table 1.
Sample size, median, 25 and 75 percentiles for OS
markers in cord blood, and P values computed by the
D’Agostino-Pearson test for normality (Sheskin, 2011) are
detailed in Table 2.
RIs, 90% CI, and medians are calculated with a right side
nonparametric method (CLSI C28-A3) for OS markers in
cord blood and are provided in Table 3.
Our data showed a “right sided” distribution with only an
upper limit of reference and no lower limit. Outliers have
been removed using the Tukey test.
In Figures 1–3, groups of numerical data through their
quartiles are graphically depicted (box and whisker plot).
Outliers are plotted as ﬁlled points.
5. Discussion
Our study was born from the need to provide reference
values for markers of OS.
Clinical laboratory data are not used if they cannot be
related with the own RIs. The value of a laboratory data is
helpful only if it is compared with the RIs.
The RIs can be a single cut, a series of cut-oﬀs, or a
range of values containing 95% of the results of a reference
population. There are more possibilities to compare the
laboratory data: the most used are the reference collective
values. These are essential for screening, detection, and mon-
itoring of diseases. They are the most used but are not
easy to produce.
They should be determined on a representative sample of
the patient population where the test will be used. The most
common deﬁnition of the RIs is the range of values con-
taining the central 95% of the healthy population. If the
reference limits are the values at 2.5% and 97.5%, the
Table 1: Demographic and clinical characteristics of the
study population.
N 120
M 58
F 62
Enrollment 1/01/2016–30/04/2016
Maternal age 30,08± 3,19
GA (wks) 39,08± 1,24
BW (g) 3247,03± 495,5
pH 7± 0,12
Apgar 9-10
N: sample number; M: male; F: female; GA: gestational age; BW:
birth weight.
Table 2: Summary statistic for oxidative stress markers in
cord blood.
Sample size Median
Percentiles
(25°–75°)
P (D’Agostino
Pearson)
AOPP 120 27.90 16.40–50.50 <0.0001
NPBI 120 0.80 0.2–3.53 <0.0001
Isoprostanes
(pg/mL)
120 66.30 41.02–83.70 <0.0001
Table 3: Reference interval—right side nonparametric method
(CLSI C28-A3) for OS markers in cord blood.
Analytes Upper limit Median
Higher 90% CI
(bootstrapa CI)
AOPP (μmol/dL) 80.39 27.90 68.94–92.28
NPBI (μmol/L) 6.91 0.80 5.48–8.30
Isoprostanes (pg/mL) 124.47 66.30 114.31–136.58
aBootstrap conﬁdence interval (500 iterations; random number seed: 400).
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other 5% of the “healthy” population is to be classiﬁed as
“abnormal” or “positive”.
These data allow you to compare the values of a patient
with the reference data of the reference population, but they
have no value for the medical decision levels.
We decided to measure F2-isoprostanes, non–protein-
bound iron (NPBI), and advanced oxidation protein products
(AOPP) as markers of OS damage since they are
considered truly speciﬁc and reliable to evaluate the OS
damage. Moreover, we used methodologies with a high
sensitivity and speciﬁcity.
The RIs were produced by following safe guidelines
edited by the Clinical and Laboratory Standard Institute used
for the making of sample collection, the process of analysis,
and statistical processing.
Speciﬁc guidelines related to production protocol are
proposed for establishing RIs. These procedures include the
choice of the preanalytical and analytical phases, the calcu-
lation methods, and the requirements for estimating valid
reference intervals [37–40].
Ideally, RIs should be determined by sampling a healthy
population using a direct sampling method (“a priori”). The
direct technique conforms to the International Federation
of Clinical Chemistry and Laboratory Medicine (IFCC)
recommendations, and it is preferred. However, the par-
ticularity of populations and the time involved in obtaining
a representative group of reference individuals may be
overcome with the indirect method. The working groups
acknowledge that, in this circumstance, it may be very diﬃ-
cult to have a priori method and they advocate the use of
indirect methods in which speciﬁc statistical tests for small
populations are applied [41–43].
In a posteriori method, all the processes (exclusion and
partition of reference individuals) occur after a biological
sample is collected and analyzed.
It involves application of statistical methods to ana-
lytical values collected in an already made database with-
out previous choice of reference individuals. The indirect
technique may have clinical utility in selected situations,
including pediatrics and the elderly population where col-
lecting a suﬃcient numbers of reference samples may be
diﬃcult [41–43].
This method is based on the concept that many results,
even on hospital patients, may be “normal.” Many studies
used data from all hospital patients to produce reference
values. In this study, we enrolled neonates that were born
healthy at the end of a physiological pregnancy and were
discharged from hospital in the second days of life.
The production of reference values seems to be quick and
easy, but it is quite a laborious process as reported in the lines
of the expert group on the reference value theory (EPTRV)
of the International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC) and in the Standing Committee
on the reference values—International Council for the stan-
dardization of procedures hematology (ICSH) [37].
In our study, the guidelines for the production of
reference values have been produced by using the C28-
A2 of the National Committee for Clinical Laboratory
Standards (NCCLS).
We choose a representative group of the population that
will be tested. The reference group should be free from
disease and conditions that could lead to an “abnormal”
result. We established criteria to exclude individuals with
factors that can aﬀect the test.
Reed et al. [42] suggest that a minimum of 120 observa-
tions, each one from a referent subject, should be available
for analysis. This has the advantage of also allowing 90%
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Figure 1: Box and whisker plot for AOPP.
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Figure 2: Box and whisker plot for NPBI.
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Figure 3: Box and whisker plot for isoprostanes.
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conﬁdence limits to be computed nonparametrically for each
reference limit.
To estimate the reference limits for these same percen-
tiles with 95% conﬁdence, a minimum of 146 reference
values are needed; for 99% conﬁdence, a minimum of
210 reference values are needed. Linnet [43] proposes that
up to 700 should be obtained for highly skewed distribu-
tions of results. However, as a standard for general prac-
tice, the working group supports the recommended
minimum of 120 reference subjects. When fewer observa-
tions are available, the use of the nonparametric method
becomes problematic. The robust method, however, oﬀers
a potential alternative.
As noted by Horn and Pesce [36], calculating the refer-
ence interval using robust methods involves an iterative
process, where the initial location (center) is estimated by
the median and the initial stairs (spread) and by the median
absolute deviation about the median (MAD). In the process,
actual observations are down weighted according to their
distance from the central tendency of the sample. The
quantity that represents the updated estimate of central
tendency is calculated for each iteration, until the change in
successive iterative values is negligible.
The decision to choose 120 cases is due to a desire to
follow, for our small population, the ICSH guidelines that
regulate the preanalytical phase and the analysis phase of
the treatment of samples. To recruit a greater number of
cases, we would have to wait more time; this could have led
to an increase in the error in the preanalytical and in the
analytical phases.
When it is not possible to reach the suggested number
of cases, Horn and Pesce [36] have proposed the robust
method as an alternative to estimate reference RIs. How-
ever, we discarded this possibility because the CI intervals
are estimated with the bootstrap [44] by using this
method. When the sample contains too many same values,
it may be impossible to calculate the CI. For NPBI, zero
concentration values were reported many times and the
CI was not calculated.
In conclusion, our study for the ﬁrst time in literature
provides reference value for the most reliable markers of
OS in newborns. These intervals are necessary for all clinical
laboratory tests, and they are an important task for produc-
ing diagnostic tests for clinical pathology.
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